Caught in the crossfire: cancer, cisplatin therapy, and kidney injury

Benjamin D. Humphreys

doi:10.1152/ajprenal.00037.2023

Caught in the crossfire: cancer, cisplatin therapy, and kidney injury

Benjamin D. Humphreys

Research output: Contribution to journal › Editorial

Original language	English
Pages (from-to)	F362-F363
Journal	American Journal of Physiology - Renal Fluid and Electrolyte Physiology
Volume	324
Issue number	4
DOIs	https://doi.org/10.1152/ajprenal.00037.2023
State	Published - Apr 2023

Access to Document

10.1152/ajprenal.00037.2023

Cite this

@article{f1536478cc1c4d2cb5c90f5fffe3630c,

title = "Caught in the crossfire: cancer, cisplatin therapy, and kidney injury",

author = "Humphreys, \{Benjamin D.\}",

note = "Funding Information: Work in the Humphreys laboratory is supported by seed network Grant CZF2019-002430 from the Chan Zuckerberg Initiative and National Institute of Diabetes and Digestive and Kidney Diseases Grants DK103740 and UC2DK126024 (all to B.D.H.). Funding Information: B.D.H. is a consultant for Janssen Research \& Development, LLC, Pfizer, and Chinook Therapeutics, holds equity in Chinook Therapeutics, and receives grant funding from Janssen Research \& Development, LLC, and Pfizer; all interests are unrelated to the current work.",

year = "2023",

month = apr,

doi = "10.1152/ajprenal.00037.2023",

language = "English",

volume = "324",

pages = "F362--F363",

journal = "American Journal of Physiology - Renal Fluid and Electrolyte Physiology",

issn = "1931-857X",

number = "4",

}

TY - JOUR

T1 - Caught in the crossfire

T2 - cancer, cisplatin therapy, and kidney injury

AU - Humphreys, Benjamin D.

N1 - Funding Information: Work in the Humphreys laboratory is supported by seed network Grant CZF2019-002430 from the Chan Zuckerberg Initiative and National Institute of Diabetes and Digestive and Kidney Diseases Grants DK103740 and UC2DK126024 (all to B.D.H.). Funding Information: B.D.H. is a consultant for Janssen Research & Development, LLC, Pfizer, and Chinook Therapeutics, holds equity in Chinook Therapeutics, and receives grant funding from Janssen Research & Development, LLC, and Pfizer; all interests are unrelated to the current work.

PY - 2023/4

Y1 - 2023/4

UR - https://www.scopus.com/pages/publications/85151043457

U2 - 10.1152/ajprenal.00037.2023

DO - 10.1152/ajprenal.00037.2023

M3 - Editorial

C2 - 36892907

AN - SCOPUS:85151043457

SN - 1931-857X

VL - 324

SP - F362-F363

JO - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

JF - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

IS - 4

ER -

Caught in the crossfire: cancer, cisplatin therapy, and kidney injury

Access to Document

Other files and links

Cite this